Author: Customer Service
Strong growth in February/March following January seasonality
Net revenue approaches US$100M since launch
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million.
Ryoncil® revenue strengthens Mesoblast’s balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product...
HII Teams with GrayMatter Robotics to Integrate Physical AI into Manned and Unmanned Shipbuilding
Written by Customer Service on . Posted in Public Companies.
CARSON, Calif., April 06, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) and GrayMatter Robotics (GMR) signed a memorandum of understanding (MOU) today to explore the integration of GMR’s Physical AI into shipbuilding operations that could accelerate throughput, strengthen the maritime industrial base, and augment the shipbuilding workforce. This will include bringing autonomous surface preparation, coating, and inspection technologies into shipbuilding. The MOU signing ceremony took place at GrayMatter Robotics’ headquarters and was attended by Eric Chewning, HII’s executive vice president of maritime systems and corporate strategy, and Ariyan Kabir, GrayMatter Robotics CEO and co-founder.
“We are in the midst of an American shipbuilding renaissance and we are extremely excited to partner with GrayMatter Robotics to explore incorporating...
Atlas Energy Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Operations and Filing of Its 2025 AIF
Written by Customer Service on . Posted in Public Companies.
CALGARY, Alberta, April 06, 2026 (GLOBE NEWSWIRE) — Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for the three months and year ended December 31, 2025, and filing of its Annual Information Form (“AIF”). Selected financial and operational information is outlined below and should be read with Atlas’ audited consolidated financial statements and management’s discussion and analysis (“MD&A”) as of December 31, 2025, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca.
“With a strong balance sheet, including approximately $27.5 million in cash and no debt as of December 31, 2025, and an experienced leadership team in place, Atlas is well positioned to execute on its growth strategy,” said Mark Hodgson, Atlas Energy’s...
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
Q1 2026 HighlightsQ1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.
ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed1.
TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted...
FTI Consulting Adds Three Leading Mining and Resources Business Improvement Experts
Written by Customer Service on . Posted in Public Companies.
SYDNEY, April 06, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointments of James Chapman, Steve Dyson and Franz Wentzel as Senior Managing Directors in its Australian Transformation practice, bringing their experience as former global heads of Big Four accounting firm mining practices to help clients realise their full value potential.
The appointments of Mr. Chapman, Mr. Dyson and Mr. Wentzel continue the firm’s growth of its Transformation – Mining team, following the recent addition of Carrie Grimes as a Senior Managing Director.
“FTI Consulting has always been about bringing together senior experts, with deep real-world experience, to work side-by-side with clients at critical times to help solve their most important issues,” said Mark Dewar, Australia Leader of FTI Consulting. “James, Steve...
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Written by Customer Service on . Posted in Public Companies.
Statistically significant (p
LGI Homes Reports March and First Quarter 2026 Home Closings and Announces Date for First Quarter Earnings Conference Call
Written by Customer Service on . Posted in Public Companies.
THE WOODLANDS, Texas, April 06, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 451 homes in March 2026, which includes the closing of 9 currently or previously leased single-family rental homes. The Company closed 916 homes during the first quarter of 2026, which includes the closing of 35 currently or previously leased single-family rental homes.
As of March 31, 2026, the Company had 142 active selling communities.
First Quarter 2026 Earnings Conference Call and Webcast
The Company plans to release financial results for the first quarter ended March 31, 2026, before the market opens on Tuesday, April 28, 2026. The Company will hold a conference call at 12:30 p.m. Eastern Time the same day to discuss the results.
A link to the live audio webcast will be provided through the Investor Relations page...
OceanFirst Financial Corp. and Flushing Financial Corporation Announce Receipt of the Requisite Shareholder Approvals for Pending Merger Transaction
Written by Customer Service on . Posted in Mergers And Acquisitions.
RED BANK, N.J. and UNIONDALE, N.Y., April 06, 2026 (GLOBE NEWSWIRE) — OceanFirst Financial Corp. (NASDAQ: “OCFC”) (“OceanFirst”), the holding company for OceanFirst Bank N.A., and Flushing Financial Corp. (NASDAQ: “FFIC”) (“Flushing”), the holding company for Flushing Bank, today jointly announced the receipt of the requisite shareholder approvals for the previously announced combination of OceanFirst and Flushing, pursuant to the Agreement and Plan of Merger, dated December 29, 2025, by and among OceanFirst, Apollo Merger Sub Corp., a Delaware corporation and wholly-owned subsidiary of OceanFirst, and Flushing (the “Merger Agreement”).
Additionally, the New York State Department of Financial Services and the Office of the Comptroller of the Currency granted their requisite approvals of the proposed transaction on March 23, 2026,...
Avicanna Announces Changes to its Board of Directors
Written by Customer Service on . Posted in Public Companies.
TORONTO, April 06, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces effective Thursday April 1, 2026 the resignation of John McVicar and pleased to announce the appointment of Mr. Ozgur Kilic to the Board of Directors of the Company.
Mr. Kilic is an experienced global business executive and Chief Executive Officer with a background as a strategic Chief Financial Officer and Chief Operating Officer with more than 20 years of experience at various global public companies and private equity backed pharma companies across the US, UK, Italy, and Switzerland. Mr. Kilic is a graduate of Koc University (BA, Business Administration; BA, History)...
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Written by Customer Service on . Posted in Public Companies.
Clinical Development Program Appropriate for Rolling BLA
Submission Expected by the End of 2025
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administration (FDA) resulting in confirmation to initiate a rolling Biologics Licenses Application (BLA) for ReNu planned before the end of December.
“We are excited about the outcome of our FDA meeting and reaching this important milestone in the ReNu program,” said Patrick Bilbo, Chief Operating Officer of Organogenesis. “We are pleased the ReNu clinical development...
